title: Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer.
abstract: We assessed the effect standard-dose induction chemotherapy and tandem cycles of high-dose chemotherapy (HDC) have on outcomes in metastatic breast cancer. One hundred and one women with metastatic breast cancer were enrolled in two non-randomized phase II studies. The first group of 64 patients (induction group) received four cycles of docetaxel 75 mg/m2 and doxorubicin 50 mg/m2. The next 37 patients did not receive induction (no induction group). Both groups received two (tandem) cycles of HDC. Blood-derived stem cells were collected after the first HDC cycle, processed using CD34+ cell selection and then reinfused after the second HDC cycle. Outcomes were compared between the two groups and also to patients participating in the Philadelphia (inter-group) randomized metastatic breast cancer transplant trial (PBT-01). Intent-to-treat analysis revealed no significant differences in complete response rates (37.5% vs 27%; P = 0.20), overall response (75% vs 71%), median progression free survival (PFS) (11.9 vs 8 months; P = 0.24) and overall survival (OS) (>36 vs 25 months; P = 0.16), in the induction vs no induction groups, respectively. Adjusting for differences in known baseline characteristics, induction group patients were found to have significantly longer PFS (P = 0.002), OS (P = 0.01) and more frequent conversion from a partial to complete response (58% vs < or = 13%, P < or = 0.0002) when compared with PBT-01 patients. Induction chemotherapy administered prior to tandem cycles of HDC does not appear to adversely affect outcomes in metastatic breast cancer patients. Outcomes in our induction group also compare favorably with those observed in PBT-01 and warrant further clinical investigation.
authors.affiliation: Hackensack University Medical Center, NJ, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Pecora
authors.forename: H M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
authors.forename: J
authors.initials: J
authors.lastname: Winter
authors.forename: A
authors.initials: A
authors.lastname: Van Vliet
authors.forename: D
authors.initials: D
authors.lastname: Berry
authors.forename: R
authors.initials: R
authors.lastname: Gray
authors.forename: A
authors.initials: A
authors.lastname: Jennis
authors.forename: S
authors.initials: S
authors.lastname: Goldberg
authors.forename: B W
authors.initials: BW
authors.lastname: Cooper
authors.forename: R
authors.initials: R
authors.lastname: Preti
mesh_terms: D000328:Adult; D018952:Antigens, CD34; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000592:standards; D001943:Breast Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000592:standards; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000592:standards; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000592:standards; D012074:Remission Induction; D016019:Survival Analysis; D043823:Taxoids; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel